Current Price
Target Price
Analyst Sentiment
11 ratings: Buy
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in S...|
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
| Metric (B) | FY 2024 | FY 2025 | FY 2025 | FY 2026 | FY 2026 | FY 2026 | FY 2026 | FY 2026 | FY 2027 |
|---|---|---|---|---|---|---|---|---|---|
| $0.00 | $-0.42 | $-0.40 | $-0.58 | $-0.50 | $-0.56 | $-1.18 | $-0.15 | $-0.65 | |
| 0.99 | 0.14 | 0.16 | 0.14 | 0.17 | 0.18 | 0.68 | 1.92 | 1.44 | |
| — | +2.3% | +4.8% | +0.0% | +0.0% | +9.6% | -14.0% | -109.4% | +37.6% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | TTarsus Pha... | TARS | $3.96B | — | 38.01 | -102.90% | -9.61% | -319.80% | 63.90% |
| 2. | ZZenas Biop... | ZBIO | $1.90B | — | 8.89 | — | -2,748.00% | -265.10% | -100.00% |
| 3. | VVerastem I... | VSTM | $1.03B | — | 102.05 | -178.40% | -193.70% | -471.20% | 113.60% |
| 4. | MMirum Phar... | MIRM | $6.14B | — | 26.59 | -134.70% | -21.60% | -760.00% | 39.60% |
| 5. | KKalVista P... | KALV | $1.44B | — | 49.03 | -118.70% | -57.40% | -190.20% | 30.70% |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|
Revenue | 823.75 | 78.45 | 156.9 | 156.9 | 233.7 | 334.13 | 334.13 | 298.88 |
COGS | 15.06 | 7.01 | 14.03 | 14.03 | 21.65 | 68.69 | 68.69 | 48.01 |
Gross Profit | 808.69 | 71.44 | 142.88 | 142.88 | 212.05 | 265.45 | 265.45 | 250.86 |
Gross Profit % | 98.17% | 91.06% | 91.06% | 91.06% | 90.74% | 79.44% | 79.44% | 83.94% |
| 620.7 | 354.83 | 709.66 | 709.66 | 766.03 | 906.3 | 906.3 | 994.82 | |
EBIT | 187.98 | -283.39 | -566.79 | -566.79 | -553.98 | -640.85 | -640.85 | -743.95 |
OPM % | 22.82% | -361.23% | -361.23% | -361.23% | -237.05% | -191.8% | -191.8% | -248.91% |
Non-Operating Income | -25.09 | 4.32 | 8.64 | 8.64 | -31.33 | 2.14 | 2.14 | -50.55 |
PBT | 162.9 | -279.07 | -558.15 | -558.15 | -585.31 | -638.72 | -638.72 | -794.51 |
Income Tax | 0.07 | 5.18 | 10.36 | 10.36 | 5.51 | 1.4 | 1.4 | 13.47 |
Tax Rate % | 0.04% | -1.86% | -1.86% | -1.86% | -0.94% | -0.22% | -0.22% | -1.7% |
Net Income | 163 | -284.22 | -568.43 | -568.43 | -590.77 | -639.96 | -639.96 | -807.68 |
NPM % | 19.79% | -362.28% | -362.28% | -362.28% | -252.79% | -191.53% | -191.53% | -270.24% |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 7.67 | 6.33 | 6.81 | 14.51 | 12.45 | 27.91 | 209.71 | 221.98 | 980.65 | 558.48 |
COGS | 0.26 | 0 | 0 | 2.1 | 1.97 | 3.33 | 22 | 30.54 | 29.09 | 131.73 |
Gross Profit | 7.41 | 6.33 | 6.81 | 12.42 | 10.48 | 24.58 | 187.71 | 191.44 | 951.57 | 426.75 |
Gross Profit % | 96.6% | 100% | 100% | 85.56% | 84.21% | 88.08% | 89.51% | 86.24% | 97.03% | 76.41% |
| 122.03 | 137 | 330.65 | 595.1 | 674.42 | 894.42 | 1,037.52 | 1,064.08 | 1,321.3 | 1,605.91 | |
EBIT | -114.62 | -130.67 | -50.25 | -582.68 | -663.94 | -869.84 | -849.81 | -872.64 | -369.73 | -1,179.16 |
OPM % | -1495% | -2064.92% | -738.14% | -4014.92% | -5332.86% | -3116.57% | -405.23% | -393.11% | -37.7% | -211.14% |
Non-Operating Income | 6.78 | 10.55 | -296.66 | -899.63 | -11.51 | 37.59 | -37.36 | -60.23 | -25.52 | -23.21 |
PBT | -107.84 | -120.12 | -346.91 | -1,482.32 | -675.45 | -832.25 | -887.17 | -932.86 | -395.25 | -1,202.37 |
Income Tax | 0 | -1.6 | -1.6 | -1.6 | 2.16 | -49.83 | -4.25 | -7.15 | 10.43 | 6.75 |
Tax Rate % | - | 1.33% | 0.46% | 0.11% | -0.32% | 5.99% | 0.48% | 0.77% | -2.64% | -0.56% |
Net Income | -107.84 | -118.51 | -345.31 | -1,480.71 | -677.61 | -782.42 | -882.92 | -925.64 | -405.43 | -1,208.91 |
NPM % | -1406.53% | -1872.85% | -5072.82% | -10202.67% | -5442.62% | -2803.38% | -421.02% | -416.98% | -41.34% | -216.47% |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 294.53 | 14.82 | 957.09 | 878.51 | 1,019.98 | 1,706.89 | 1,475.64 | 1,069.3 | 1,236.58 | 2,471.66 | |
| 157.39 | 384.17 | 14.4 | 0 | 0 | 27.84 | 37.23 | 23.35 | 39.23 | 37.03 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 11.79 | 15.75 | 18.73 | 30.59 | 59.06 | 178.39 | 160.85 | 274.88 | 237.58 | 474.39 | |
| 129.63 | 166.93 | 239.16 | 295.94 | 652 | 1,026.93 | 1,156.54 | 1,132.86 | 1,104.42 | 983.02 | |
Total Assets | 593.34 | 581.66 | 1,229.38 | 1,205.05 | 1,731.04 | 2,940.06 | 2,830.26 | 2,500.39 | 2,617.81 | 3,966.1 |
| 0 | 0 | 0.06 | 0.14 | 0.15 | 0.18 | 0.18 | 0.2 | 0.21 | 0.26 | |
| -14.61 | -131.8 | -1,011.65 | 890.33 | 846.47 | 1,234.56 | 408.48 | 60.22 | 263.98 | 1,325.05 | |
| 0.83 | 4.9 | 42.04 | 101.41 | 529.7 | 1,084.29 | 1,792.73 | 1,795.6 | 1,668.5 | 1,980.98 | |
| 78.44 | 79.41 | 66.68 | 108.26 | 219.6 | 308.38 | 331.24 | 270.97 | 323.84 | 383.65 | |
| 528.68 | 629.15 | 2,132.24 | 104.91 | 135.13 | 312.65 | 297.64 | 363.2 | 351.31 | 266.41 | |
Total Liabilities | 593.34 | 581.66 | 1,229.38 | 1,205.05 | 1,731.04 | 2,940.06 | 2,830.26 | 2,490.18 | 2,607.84 | 3,956.34 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| -45.89 | -107.98 | -237.67 | -460.31 | -609.96 | -604.68 | -653.91 | -726.08 | -111.36 | -1,174.13 | |
| -152.61 | -230.35 | 292.81 | -201.33 | -107.37 | -466.52 | -384.61 | 21.92 | -362.04 | -1,000.05 | |
| 435.54 | 58.36 | 860.16 | 442.36 | 1,040 | 1,781.39 | 619.27 | 368.75 | 314.77 | 2,540.1 | |
Net CFNet Cash Flow | 237.03 | -279.97 | 915.3 | -219.28 | 322.68 | 710.19 | -419.26 | -335.4 | -158.63 | 365.92 |
FCFFree Cash Flow | -49.26 | -128.52 | -287.13 | -541.72 | -861.43 | -1,041.31 | -890.88 | -782.92 | -135.65 | -1,201.7 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 161.9% | 60.4% | 2445.2% | -78.0% | -75.2% | -107.5% | -394.7% | -249.8% | -152.1% | |
| -0.06 | -0.04 | -0.04 | 0.11 | 0.63 | 0.88 | 4.39 | 29.72 | 6.32 | 1.49 | |
| 5.97 | 5.21 | 9.41 | 4.50 | 3.91 | 5.22 | 1.86 | 1.44 | 1.26 | 1.79 | |
| - | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.07 | 0.08 | 0.38 | 0.17 | |
Cash Conversion | 0.43 | 0.91 | 0.69 | 0.31 | 0.90 | 0.77 | 0.74 | 0.78 | 0.27 | 0.97 |
Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| - | -17.5% | 7.6% | 113.2% | -14.2% | 124.2% | 651.4% | 5.9% | 341.8% | -43.1% | |
| - | - | - | - | - | - | - | - | - | - | |
| - | - | - | - | - | - | - | - | - | - | |
| 2.00 | 2.00 | 4.00 | 3.00 | 2.00 | 5.00 | 3.00 | 2.00 | 5.00 | 3.00 | |
| - | -2.60 | -3.35 | -6.34 | -3.65 | 43.69 | 2.22 | -1.39 | -0.68 | 0.17 | |
| 100.00 | 100.00 | 100.00 | 66.67 | 53.33 | 53.33 | 33.33 | 33.33 | 33.33 | 46.67 | |
| -14.1% | -18.7% | -50.7% | -102.0% | -54.4% | -28.0% | -4.2% | -4.2% | -0.4% | -2.2% |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns Ascentage Pharma Group International, from SEC filings
No SEC ownership filings for this company yet.
Ascentage Pharma Group International's SEC filings and earnings call transcripts
No SEC filings for this company yet.
What recent news says about Ascentage Pharma Group International, scored for sentiment.